The initial success of Sildenafil undeniably transformed the medication landscape, but placing funds in companies heavily reliant on generic versions presents a uncertain picture. Despite early returns were substantial, the cessation of patents and the rise of cheaper alternatives have diminished sales. Thus, a thorough evaluation of present revenu